NEW YORK, July 01, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Hims & Hers Health, Inc. (“Hims & Hers” or the “Company”) (NYSE: HIMS). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased. The class action concerns whether Hims & Hers and cert ...

Core Insights - The United Kingdom telehealth market was valued at USD 21.56 Billion in 2024 and is projected to grow at a CAGR of 12.10%, reaching USD 67.56 Billion by 2034, driven by increased internet access and smartphone penetration [2][10] - Strong policy support from the NHS and the UK government is facilitating the adoption of telehealth services, ensuring funding and integration within public healthcare frameworks [2] Market Growth Drivers - The UK government announced an investment of up to EUR 600 million (USD 764 million) for a centralized Health Data Research Service, aimed at enhancing data access for researchers and accelerating clinical trials, which is expected to significantly boost telehealth market growth [4] - Rising demand for remote inpatient care and AI-driven solutions, such as Teladoc's AI-powered Virtual Sitter, are enhancing patient safety and care efficiency, contributing to market value growth [5] - User-centric telehealth platforms, like Doctorsa's global telehealth platform, are addressing increasing wait times for GP appointments and improving patient satisfaction, thereby driving market development [5] Market Trends - AI-powered tools for women's health, such as Moody's mental health tool, are expanding the telehealth market by providing personalized care solutions [8] - Investment in virtual wards, exemplified by West Suffolk NHS Foundation Trust's tender for remote patient monitoring services, is expected to enhance clinical outcomes and operational efficiency [8] - Digital therapeutics are gaining traction, offering validated software-based interventions for chronic conditions, supported by NHS initiatives [8] Market Segmentation - The services segment is anticipated to lead the market due to its role in enabling seamless virtual care delivery, particularly in managing chronic diseases and elderly care [8] - England is expected to dominate the market, supported by a robust NHS digital infrastructure and a high urban population, while Scotland, Wales, and Northern Ireland are progressing at varying rates [8] Key Players - Major companies in the UK telehealth market include Doctor Care Anywhere, Teladoc Health, Livi, Babylon Health, Medicspot, Push Doctor, eConsult Health, Cisco Systems Inc., and Codal [7][19]

SAN FRANCISCO, June 30, 2025 (GLOBE NEWSWIRE) -- On June 25, 2025, two securities class action lawsuits were filed against Hims & Hers Health, Inc. (NYSE: HIMS) and certain of the company’s executives. Sookdeo v. Hims & Hers Health, Inc., et al., No. 3:25-cv-05315 (N.D. Cal.) and Yaghsizian v. Hims & Hers Health, Inc. et al., No. 3:25-cv-05321 (N.D. Cal.). Together, the cases seek to represent investors who purchased or otherwise acquired Hims & Hers securities between April 29, 2025 and June 23, 2025. The ...

Core Insights - Virtual healthcare services, or telehealth, are becoming a standard in the digital healthcare space, with companies like Hims & Hers Health, Inc. (HIMS) and LifeMD, Inc. (LFMD) emerging as key players providing direct-to-consumer services [1][2] Company Overview - Hims & Hers is focused on transforming health and wellness needs for consumers, while LifeMD offers cost-effective telehealth solutions for comprehensive virtual and in-home healthcare [2] - HIMS is expanding into Europe through the acquisition of ZAVA, targeting markets such as Germany and France, while LFMD's Wegovy program has enrolled over 75,000 patients, indicating strong market traction [6][8][10] Stock Performance & Valuation - Over the past three months, HIMS has increased by 67.2%, while LFMD has risen by 152.8%. However, in the past year, HIMS has gained 130.7% compared to LFMD's 102.2% [3] - HIMS has a forward price-to-sales (P/S) ratio of 4.3, above its three-year median of 2.3, while LFMD's ratio is 2.2, also above its median of 0.9 [5] Earnings Projections - HIMS expects a 170.4% growth in EPS for 2025, compared to LFMD's projected 107.6% growth [6][15][17] - The Zacks Consensus Estimate for HIMS' 2025 EPS suggests a significant improvement from 2024, while LFMD's estimate also indicates growth [15][17] Strategic Initiatives - HIMS is focusing on expanding into new specialty areas that can be treated via telehealth, such as sleep disorders and hypertension, which align with its business model [7] - LifeMD's Wegovy program integrates medication with virtual care, providing a compliant solution for weight loss therapy, which is in high demand [10][11] Financial Health - LifeMD reported first-quarter revenues of $65.7 million and net income of $1.4 million, showing a turnaround from previous losses, supported by $34.4 million in cash [12] - HIMS is utilizing proceeds from its $870 million convertible senior notes offering to support global expansion and investment in AI and personalized treatments [9] Investment Outlook - HIMS is viewed as a more stable investment opportunity with strong profitability and user engagement, while LFMD is recognized for its rapid growth and expansion [24][25] - Analysts have set average price targets for HIMS at $46.17 and for LFMD at $12.81, both indicating potential declines from their last close [20][22]

SAN DIEGO, June 30, 2025 /PRNewswire/ -- The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Hims & Hers Health, Inc. (NYSE: HIMS) securities between April 29, 2025 and June 23, 2025, both dates inclusive (the "Class Period"), have until August 25, 2025 to seek appointment as lead plaintiff of the Hims & Hers class action lawsuit. Captioned Sookdeo v. Hims & Hers Health, Inc., No. 25-cv-05315 (N.D. Cal.), the Hims & Hers class action lawsuit charges Hims & Hers as well ...

Core Viewpoint - Hims & Hers Health, Inc. is facing a class action lawsuit due to allegations of deceptive practices related to the promotion and sale of illegitimate versions of the drug Wegovy, resulting in a significant drop in stock price following the termination of its partnership with Novo Nordisk [1][3]. Group 1: Lawsuit Details - The class action lawsuit, Sookdeo v. Hims & Hers Health, Inc., involves allegations that Hims & Hers and its executives violated the Securities Exchange Act of 1934 [1]. - The lawsuit claims that Hims & Hers engaged in deceptive promotion and selling of illegitimate versions of Wegovy, which jeopardized patient safety [2]. - Following the announcement of the termination of the partnership with Novo Nordisk on June 23, 2025, Hims & Hers' stock price fell by more than 34% [3]. Group 2: Legal Process - Investors who purchased Hims & Hers securities during the class period (April 29, 2025, to June 23, 2025) can seek appointment as lead plaintiff in the class action lawsuit [4]. - The lead plaintiff will represent the interests of all class members and can choose a law firm to litigate the case [4]. Group 3: Company Background - Hims & Hers is a telehealth company that provides prescription medications, over-the-counter medications, and personal care products [2]. - Robbins Geller Rudman & Dowd LLP, the law firm handling the case, is recognized for its success in securities fraud and shareholder litigation, having recovered over $2.5 billion for investors in 2024 alone [5].

Core Viewpoint - The healthcare sector is highlighted as a critical area in the stock market, driven by the need for innovative therapies and medical technologies to address an aging population and rising chronic diseases. There are ten under-the-radar healthcare stocks identified as potential investment opportunities. Group 1: Company Highlights - **Certara**: Positioned to benefit from AI-driven transformations in medicine, providing bio-simulation software that accelerates drug development, with over 90% of novel drugs approved by the FDA since 2014 utilizing its technology [3][4]. - **Beam Therapeutics**: A clinical-stage biotech focusing on precision gene editing therapies for genetic diseases, with its lead candidate in phase 1/2 trials for sickle cell disease, showing promise for long-term growth [5][6]. - **Inspire Medical Systems**: Develops implantable devices for obstructive sleep apnea, reporting a 23% year-over-year revenue increase to $201 million, indicating strong market demand [8]. - **Insulet**: Specializes in tubeless insulin pump technology, targeting a revenue growth of 19% to 22% by 2025, with significant expansion opportunities in international markets [9]. - **Krystal Biotech**: Focuses on rare skin diseases, with its gene therapy expected to generate approximately $400 million in revenue this year, reinforcing its market position [10]. - **LifeMD**: Operates a telehealth platform with a 49% year-over-year revenue increase, driven by a partnership with Novo Nordisk, indicating potential for further growth [11]. - **Option Care Health**: Leading provider of home infusion services, positioned to benefit from the shift towards personalized healthcare [12]. - **Tempus AI**: Utilizes AI for precision medicine, projecting over 80% revenue growth this year to about $1.3 billion, highlighting its expansive data ecosystem [13]. - **TransMedics Group**: Innovates in organ transplantation with its FDA-approved Organ Care System, projecting a 30% revenue growth this year [14][15]. - **Veeva Systems**: Offers cloud-based software for life sciences, serving over 1,000 customers and positioned to capitalize on the industry's digital transformation [16].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Hims & Hers Health, Inc. due to allegations of misleading statements and the termination of its partnership with Novo Nordisk, which has significantly impacted the company's stock price [3][5][6]. Group 1: Legal Investigation and Claims - Faruqi & Faruqi is encouraging investors who suffered losses exceeding $50,000 in Hims between April 29, 2025, and June 23, 2025, to discuss their legal options [1]. - A federal securities class action has been filed against Hims, with a deadline of August 25, 2025, for investors to seek the role of lead plaintiff [3][7]. - The firm has a history of recovering hundreds of millions of dollars for investors since its founding in 1995 [4]. Group 2: Allegations Against Hims - The complaint alleges that Hims and its executives violated federal securities laws by making false or misleading statements regarding the safety and legitimacy of their products [5]. - Specific allegations include the deceptive promotion of illegitimate versions of Wegovy® and the risk of termination of collaboration with Novo Nordisk due to these practices [5][6]. - Following the announcement of the partnership termination by Novo Nordisk, Hims' stock price fell by $22.24, or 34.6%, closing at $41.98 per share on June 23, 2025 [6]. Group 3: Call for Information - Faruqi & Faruqi is also seeking information from whistleblowers, former employees, and shareholders regarding Hims' conduct [8].

Core Viewpoint - Hims & Hers Health, Inc. is facing securities class action lawsuits due to allegations of failing to disclose material information during the class period, which has led to a significant drop in share price following a partnership termination announcement by Novo Nordisk [3][4]. Group 1: Lawsuit Details - Investors have until August 25, 2025, to file lead plaintiff applications in the securities class action lawsuits against Hims, specifically for those who purchased securities between April 29, 2025, and June 23, 2025 [1]. - The lawsuits are pending in the United States District Court for the Northern District of California, with the first case being Sookdeo v. Hims & Hers Health, Inc. and a subsequent case expanding the class period [5]. Group 2: Company Impact - On June 23, 2025, Novo Nordisk announced the termination of its partnership with Hims, citing violations of laws regarding the sale of compounded drugs and concerns over patient safety due to potentially unsafe ingredients in products sold by Hims [4]. - Following this announcement, Hims' share price fell by $22.24, or 34.6%, closing at $41.98 per share on unusually heavy trading volume [4].

Core Viewpoint - A class action lawsuit has been filed against Hims & Hers Health, Inc. concerning allegations of securities fraud and unlawful business practices [2][3]. Group 1: Lawsuit Details - The lawsuit involves claims that Hims & Hers and certain officers/directors engaged in securities fraud or other unlawful business practices [2]. - Investors who purchased Hims & Hers securities during the Class Period have until August 25, 2025, to request to be appointed as Lead Plaintiff [3]. Group 2: Partnership and Stock Impact - On April 29, 2025, Hims & Hers announced a collaboration with Novo Nordisk to sell a bundled offering of Wegovy® [3]. - On June 23, 2025, Novo Nordisk terminated its partnership with Hims & Hers, citing deceptive promotion and selling of illegitimate versions of Wegovy® that jeopardized patient safety [3]. - Following the termination announcement, Hims & Hers' stock price dropped by $22.24, or 34.63%, closing at $41.98 per share [3].